[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicenna Thera Corp (MDNAF)

Medicenna Thera Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 26,739
  • Shares Outstanding, K 92,300
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,480 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.01
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.05 on 02/12/26
  • Next Earnings Date 06/24/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 1
  • High Estimate $-0.05
  • Low Estimate $-0.05
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2652 +11.61%
on 06/03/26
0.3980 -25.63%
on 05/18/26
-0.1025 (-25.72%)
since 05/15/26
3-Month
0.2652 +11.61%
on 06/03/26
0.5600 -47.14%
on 03/18/26
-0.2624 (-46.99%)
since 03/17/26
52-Week
0.2652 +11.61%
on 06/03/26
1.4300 -79.30%
on 10/27/25
-0.3649 (-55.21%)
since 06/17/25

Most Recent Stories

More News
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses  Up to 80 patients with...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Launch of a Marketed Public Offering of Securities

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)

Business Summary

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 0.3112
2nd Resistance Point 0.3069
1st Resistance Point 0.2983
Last Price 0.2960
1st Support Level 0.2854
2nd Support Level 0.2811
3rd Support Level 0.2725

See More

52-Week High 1.4300
Fibonacci 61.8% 0.9850
Fibonacci 50% 0.8476
Fibonacci 38.2% 0.7102
Last Price 0.2960
52-Week Low 0.2652

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.